Tech Company Financing Transactions

ProNAi Therapeutics Funding Round

ProNAi Therapeutics closed a $59.5 million Series D funding round on 4/22/2014. Backers included Vivo Capital, Adams Street Partners and Apjohn Ventures.

Transaction Overview

Company Name
ProNAi Therapeutics
Announced On
4/22/2014
Transaction Type
Venture Equity
Amount
$59,500,000
Round
Series D
Investors

Vivo Capital (Lead Investor) (Albert Cha)

Adams Street Partners

Apjohn Ventures (Donald Parfet)

Capital Midwest Fund (Alvin Vitangcol)

Caxton Advantage Life Sciences

Frazier Healthcare Partners (James Topper)

Hopen Life Science Ventures

Janus Capital

OrbiMed (Peter Thompson)

RA Capital

Sectoral Asset Management

Proceeds Purpose
The Series D funding will be used to advance PNT2258 in several Phase II clinical studies in patients with relapsed or treatment refractory non-Hodgkin's lymphoma including those with diffuse large B-cell lymphoma (DLBCL),Richter's transformation, and follicular lymphoma (FL). Proceeds will also be used to support drug manufacturing, advance development of preclinical drug candidates, and build ProNAi's organization in Michigan.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
885 West Georgia St. 2150
Vancouver BC, V6C 3E8
Canada
Phone
(604) 558-6536
Website
www.pronai.com
Email Address
[email protected]
Overview
ProNAi Therapeutics, Inc. (NASDAQ: DNAI) is a biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.
Profile
ProNAi Therapeutics LinkedIn Company Profile
Social Media
ProNAi Therapeutics Company Twitter Account
Company News
ProNAi Therapeutics News
Facebook
ProNAi Therapeutics on Facebook
YouTube
ProNAi Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nick Glover
  Nick Glover LinkedIn Profile  Nick Glover Twitter Account  Nick Glover News  Nick Glover on Facebook
Chief Financial Officer
Sukhi Jagpal
  Sukhi Jagpal LinkedIn Profile  Sukhi Jagpal Twitter Account  Sukhi Jagpal News  Sukhi Jagpal on Facebook
VP - Human Resources
Diane Gardiner
  Diane Gardiner LinkedIn Profile  Diane Gardiner Twitter Account  Diane Gardiner News  Diane Gardiner on Facebook
VP - Manufacturing
Simon Eastman
  Simon Eastman LinkedIn Profile  Simon Eastman Twitter Account  Simon Eastman News  Simon Eastman on Facebook
VP - Operations
Wendy Chapman
  Wendy Chapman LinkedIn Profile  Wendy Chapman Twitter Account  Wendy Chapman News  Wendy Chapman on Facebook
VP - R & D
Emma McCann
  Emma McCann LinkedIn Profile  Emma McCann Twitter Account  Emma McCann News  Emma McCann on Facebook
VP - Regulatory Affairs
Chandra Lovejoy
  Chandra Lovejoy LinkedIn Profile  Chandra Lovejoy Twitter Account  Chandra Lovejoy News  Chandra Lovejoy on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/22/2014: Orthopaedic Synergy venture capital transaction
Next: 4/22/2014: Weebly venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on every notable VC transaction. All VC database entries on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.